Celcuity Inc. 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report. Celcuity is a clinical-stage biotechnology company with no product revenue to date. Its lead candidate, gedatolisib, is being developed for solid tumors; its CELsignia platform analyzes live tumor cells to identify patients potentially responsive to targeted therapies.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $60.6 million | $35.3 million |
| General and administrative expense | $5.6 million | $4.1 million |
| Total operating expenses | $66.2 million | $39.4 million |
| Net loss | $63.8 million | $40.4 million |
| Net loss per share, basic and diluted | $2.69 | $2.64 |
| Net cash used in operations | $53.8 million | $36.0 million |
With no revenue, gross margin and revenue-based margins are not meaningful. Interest income was $7.8 million in 2023, versus $1.1 million in 2022; interest expense was $5.3 million, versus $2.1 million. These items partly offset the operating loss.
- Liquidity: At year-end, cash and cash equivalents were $30.7 million and short-term investments were $149.9 million, totaling approximately $180.6 million. Current assets were $190.6 million and current liabilities were $14.2 million.
- Debt: The balance sheet reported $37.0 million of non-current debt, including accrued payment-in-kind interest; stated loan principal was $35.0 million. The Innovatus facility provides potential additional tranches, subject to milestones, covenants and other conditions. Loans mature in April 2027.
- Cash flows: Investing activities used $5.0 million; financing activities provided $64.9 million. Year-end cash and cash equivalents increased by $6.1 million.
- Capital structure: Common shares outstanding were 25.5 million at year-end 2023. The October 2023 private placement raised approximately $50 million through pre-funded warrants for up to 5.75 million shares; the December 2023 ATM sale raised $15 million gross. Additional outstanding warrants, preferred stock and equity awards create potential dilution.
Material changes versus 2022
- Net loss increased by $23.4 million, or 58%; operating expenses rose 68%. R&D expense grew 72%, primarily due to VIKTORIA-1 Phase 3 trial costs, which accounted for most of the increase.
- Operating cash use increased by $17.8 million. Higher cash and investment balances and market interest rates drove the increase in interest income.
- Financing included approximately $50 million gross from pre-funded warrants and $15 million gross from the ATM offering. The prior year included a $100 million private placement and loan proceeds.
- Cash and short-term investments rose to approximately $180.6 million from $168.6 million. Debt carrying value increased to $37.0 million from $35.0 million, primarily reflecting PIK interest.
Business developments, outlook and risks
- Gedatolisib: VIKTORIA-1, an ongoing Phase 3 trial in HR+/HER2- advanced breast cancer after CDK4/6 therapy, was designed for approximately 701 participants and compares gedatolisib regimens with fulvestrant or alpelisib-based controls according to PIK3CA status. The filing reports no Phase 3 results. The company also reported that the first patient in its Phase 1b/2 prostate cancer study, CELC-G-201, was dosed in February 2024.
- Earlier clinical data: Celcuity reported encouraging response and safety findings from a 138-patient Phase 1b breast cancer study. These are preliminary, non-registrational results and do not establish that gedatolisib will obtain approval.
- CELsignia: Three partner-supported clinical studies were underway. The company terminated the FACT-2 trial in 2023 after new treatment options impaired enrollment feasibility. It expected FACT-1 results in the first half of 2025.
- Management outlook: Celcuity expects R&D and G&A spending to increase as trials and development activities advance. It believes year-end resources and available Innovatus borrowings will fund its current operating plan through at least 2025, but this depends on assumptions and access to conditional debt tranches. No specific revenue, earnings or approval guidance is provided.
- Key risks: Clinical results, enrollment, regulatory review, manufacturing and third-party execution are uncertain. The company has no approved product or revenue and expects ongoing losses; future capital raises may dilute shareholders. Other material exposures include dependence on Pfizer-licensed gedatolisib rights, reimbursement and pricing uncertainty, competition, patent protection, and compliance and cybersecurity risks. Pfizer may be entitled to up to $335 million in development and commercial milestones and tiered royalties in the low-to-mid teens on gedatolisib sales.
- Other items: The independent auditor issued an unqualified opinion and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. No material legal proceedings were reported.
Important facts for investors to verify
- VIKTORIA-1 enrollment, timelines and eventual primary-endpoint results, including outcomes by PIK3CA status.
- CELC-G-201 dose selection, safety findings and six-month radiographic progression-free survival results.
- Actual cash burn versus management’s runway assumptions, and whether Innovatus milestone and covenant conditions permit additional borrowing.
- Potential dilution from pre-funded warrants, other warrants, preferred shares, equity awards and further ATM sales; note a March 2024 warrant exercise generated approximately $14 million.
- FACT-1 progress and whether CELsignia studies support diagnostic partnerships, regulatory pathways and reimbursement.